Chordia Therapeutics (TSE:190A) Research & Development: 円0.00 Mil (TTM As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:190A Chordia Therapeutics Inc TSE:190A
11 GF Score
Price 円77.00
! 1 Warning Sign
View Full Analysis

What is Chordia Therapeutics Research & Development?

Chordia Therapeutics TSE:190A -2.53% 11 Research & Development is 円0.00 Mil as of Feb. 2026. GuruFocus rates TSE:190A with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Chordia Therapeutics's Research & Development for the six months ended in Feb. 2026 was 円0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Feb. 2026 was 円0.00 Mil.

Chordia Therapeutics  (TSE:190A) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Chordia Therapeutics Research & Development Related Terms

Chordia Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Chordia Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics Research & Development Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Research & Development
1,322.95 1,656.11 0.00 0.00 0.00

Chordia Therapeutics Semi-Annual Data
Aug21 Aug22 Aug23 Feb24 Aug24 Feb25 Aug25 Feb26
Research & Development Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
TSE:190A
11GF Score
Chordia Therapeutics Inc TSE:190A
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordia Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Feb. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円0.00 Mil mean?
Chordia Therapeutics (TSE:190A) has a Research & Development of 円0.00 Mil as of Feb. 2026. Research and development expense is the total cost for research and development activities. View historical data on Chordia Therapeutics and its competitors.
Is Chordia Therapeutics' Research & Development too high?
Chordia Therapeutics' current Research & Development is 円0.00 Mil. Overall, Chordia Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Chordia Therapeutics' Research & Development compare to VRTX and REGN?
Chordia Therapeutics' Research & Development of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Chordia Therapeutics and its competitors. Chordia Therapeutics's current Research & Development is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordia Therapeutics stock overvalued right now?
Chordia Therapeutics (TSE:190A) has a current Research & Development of 円0.00 Mil. The current Research & Development is 円0.00 Mil. Chordia Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Chordia Therapeutics (TSE:190A), the current Research & Development is 円0.00 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordia Therapeutics Business Description

Address 2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
11GF Score

Get the complete analysis for TSE:190A

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円77.00
Price